leisure time -WSS

leisure time

author：hotspot 2025-09-30 17:44:47 - browse：5644

Duchenne muscular dystrophy is a devastating disease and, until very recently, was one without much hope. When Hawken Miller was diagnosed at age 5, the physician told his parents to enjoy the time they had with him, as there wouldn’t be much. Over 20 years later, Miller is a journalist and content strategist for CureDuchenne, an organization started by his mother when he was diagnosed, and new treatment is on the horizon.

Last month, the FDA approved a new gene therapy from Sarepta Therapeutics that will provide hope for many patients and families. The new drug, however, has its limitations — it’s only approved for children age 4-5, for example. Miller joined the podcast to discuss how this drug may change lives, what more needs to happen, and what his personal experience has been living with Duchenne.

“For the older boys, we’re running up against the clock a little bit with what we’re able to do and what we’re not able to do,” Miller said. “And if we’re able to try anything that could possibly help, I think most people would like the opportunity to do that.”

The conversation is based off his recent First Opinion, “The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： STAT Boddities: What happens to the brain when we get scared?

focus

WSS

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Latigo launches with $135 million for Vertex

Artificial intelligence use in health care faces greater scrutiny in 2024

Astellas still sees hope in its gene therapy after four deaths

Latigo launches with $135 million for Vertex

Juul documents reveal insider tactics on political lobbying

leisure time

leisure time

knowledge

Sports medicine is finally prioritizing gender equality

Eli Lilly reports tirzepatide MASH success during Q4 earnings

23andMe had bad news about my health. I wish a person had delivered it

Why medical students are struggling with mental health

Wildfire smoke exposes gaps in outdoor worker protections

Congress must protect the remaining independent doctors

What does generative AI mean for health care? We asked experts

Why don't Americans have at

Psychedelics group wrestles with new pharma identity

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

explore

STAT Boddities: What happens to the brain when we get scared?

Report cites 'urgent' need to recruit more diverse clinical trial participants

AMAs digital advisors table RPM coding reform proposal, again

Eli Lilly reports tirzepatide MASH success during Q4 earnings

A daunting task: navigating dual Medicare, Medicaid eligibility

Why don't Americans have at

focus

Wikipedia

focus

focus